Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03065400 · ClinicalTrials.gov registry record · Phase 2
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
A Phase 2 study, sponsored by John Mascarenhas.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03065400 is a Phase 2 study that has completed, run by John Mascarenhas. The registered enrollment target is 10 participants.
The verdict
NCT03065400, a Phase 2 study, has completed, sponsored by John Mascarenhas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase (MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of the bone marrow in which excessive cells are produced. Pembrolizumab also known as Keytruda is a drug that has recently been approved in the United Stated by the Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma and disease progression. Pembrolizumab is experimental in the treatment of MPN. The researchers want to find out what effects, good and /or bad it has on participants and the disease. Participants qualify to take part in this research study if have been diagnosed with a MPN blood disorder called myelofibrosis (MF). Accelerated (10-19% blasts in the blood or bone marrow) and blast phase (\>20% blasts in the blood or bone marrow) MPN has been a difficult disease to treat. The term "blasts" refers to immature cells found in the bone marrow. They are not fully developed, and therefore, do not yet carry out any particular function within the body. Funds for conducting this research are provided by Merck and Company, the manufacturer of the study drug pembrolizumab.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2020-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03065400
The ClinicalTrials.gov registry entry for NCT03065400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Mascarenhas, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03065400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03065400 about?
NCT03065400 is a clinical study titled "PD-1 Inhibition in Advanced Myeloproliferative Neoplasms". The purpose of this study is to test the effectiveness of a drug called pembrolizumab in patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase (MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of the bone marrow in which excessi...
What is the current status of trial NCT03065400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-06-14. Estimated completion is 2020-05-28.
What interventions are being tested in trial NCT03065400?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03065400?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.